Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Pharmaceuticals to Present at BIO CEO & Investor Conference
SAN DIEGO, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentation to provide an overview of the company's programs and
View HTML
Toggle Summary Conatus Pharmaceuticals Updates Development Strategy and 2014 Milestones
Leveraging Orphan Drug Designation in Clinical Trial for Liver Transplant Recipients
View HTML
Toggle Summary Conatus Pharmaceuticals to Ring The NASDAQ Stock Market Opening Bell in Celebration of 2013 Milestones
-- Live Webcast Available at 9:15 am ET -- SAN DIEGO, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, will ring the Opening Bell at the NASDAQ MarketSite
View HTML
Toggle Summary Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver Transplant Recipients With Reestablished Fibrosis
SAN DIEGO, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug
View HTML
Toggle Summary Conatus Pharmaceuticals to Present at Piper Jaffray and Oppenheimer Healthcare Conferences in December
SAN DIEGO, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present at the following upcoming conferences in
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Third Quarter 2013 Financial Results
Management to Host Conference Call Today at 4:30 pm ET
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Third Quarter 2013 Financial Results on November 14, 2013
Conference Call Scheduled for November 14, 2013 at 4:30 p.m. ET
View HTML
Toggle Summary Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting(R)
Normal levels of apoptosis and caspase activity in healthy volunteers are not reduced by emricasan Emricasan currently in Phase 2b study in acute-on-chronic liver failure and Phase 2 study in severe alcoholic hepatitis SAN DIEGO, Nov. 2, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals
View HTML
Toggle Summary Conatus Pharmaceuticals to Present at the 12th Annual BIO Investor Forum
SAN DIEGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present a company overview at the 12 th Annual BIO
View HTML
Toggle Summary Conatus Pharmaceuticals to Join Russell Indices on September 30, 2013
SAN DIEGO, Sept. 24, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will be included in the Russell 2000®, Russell 3000® and Russell
View HTML